{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,5]],"date-time":"2026-04-05T10:21:40Z","timestamp":1775384500246,"version":"3.50.1"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001824","name":"Czech Science Foundation","doi-asserted-by":"crossref","award":["GACR 17-16169S"],"award-info":[{"award-number":["GACR 17-16169S"]}],"id":[{"id":"10.13039\/501100001824","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Reproductive Toxicology"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.reprotox.2018.05.008","type":"journal-article","created":{"date-parts":[[2018,5,30]],"date-time":"2018-05-30T13:19:08Z","timestamp":1527686348000},"page":"57-65","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Interactions of protease inhibitors atazanavir and ritonavir with ABCB1, ABCG2, and ABCC2 transporters: Effect on transplacental disposition in rats"],"prefix":"10.1016","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1313-306X","authenticated-orcid":false,"given":"Lukas","family":"Cerveny","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zuzana","family":"Ptackova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marketa","family":"Durisova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frantisek","family":"Staud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.reprotox.2018.05.008_bib0005","series-title":"Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States","author":"Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission","year":"2018"},{"issue":"10","key":"10.1016\/j.reprotox.2018.05.008_bib0010","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s40262-014-0167-9","article-title":"Pharmacokinetic enhancers in HIV therapeutics","volume":"53","author":"Larson","year":"2014","journal-title":"Clin. Pharmacokinet."},{"issue":"1","key":"10.1016\/j.reprotox.2018.05.008_bib0015","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/hiv.12277","article-title":"Lopinavir and atazanavir in pregnancy: comparable infant outcomes, virological efficacies and preterm delivery rates","volume":"17","author":"Perry","year":"2016","journal-title":"HIV Med."},{"issue":"18","key":"10.1016\/j.reprotox.2018.05.008_bib0020","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1097\/00002030-200312050-00007","article-title":"Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results","volume":"17","author":"Murphy","year":"2003","journal-title":"AIDS"},{"issue":"14","key":"10.1016\/j.reprotox.2018.05.008_bib0025","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1097\/01.aids.0000244200.11006.55","article-title":"Effects of atazanavir\/ritonavir and lopinavir\/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically","volume":"20","author":"Noor","year":"2006","journal-title":"AIDS"},{"issue":"5","key":"10.1016\/j.reprotox.2018.05.008_bib0030","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/j.1468-1293.2008.00690.x","article-title":"Effects of Ritonavir-boosted darunavir vs. Ritonavir-boosted atazanavir on lipid and glucose parameters in HIV-negative, healthy volunteers","volume":"10","author":"Tomaka","year":"2009","journal-title":"HIV Med."},{"issue":"4","key":"10.1016\/j.reprotox.2018.05.008_bib0035","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.jvir.2009.11.023","article-title":"The prevalence, risk factors, and clinical outcome of balloon rupture in balloon-occluded retrograde transvenous obliteration of gastric varices","volume":"21","author":"Park","year":"2010","journal-title":"J. Vasc. Interv. Radiol."},{"issue":"5","key":"10.1016\/j.reprotox.2018.05.008_bib0040","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1093\/jac\/dkt497","article-title":"Atazanavir and lopinavir profile in pregnant women with HIV: tolerability, activity and pregnancy outcomes in an observational national study","volume":"69","author":"Floridia","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"issue":"5","key":"10.1016\/j.reprotox.2018.05.008_bib0045","doi-asserted-by":"crossref","first-page":"507","DOI":"10.3851\/IMP2936","article-title":"Pharmacokinetics, safety and efficacy of ritonavir-boosted atazanavir (300\/100 mg once daily) in HIV-1-infected pregnant women","volume":"20","author":"Le","year":"2015","journal-title":"Antivir. Ther."},{"issue":"1","key":"10.1016\/j.reprotox.2018.05.008_bib0050","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/jamapediatrics.2014.1889","article-title":"Congenital anomalies and in utero antiretroviral exposure in human immunodeficiency virus-exposed uninfected infants","volume":"169","author":"Williams","year":"2015","journal-title":"JAMA Pediatr."},{"issue":"10","key":"10.1016\/j.reprotox.2018.05.008_bib0055","doi-asserted-by":"crossref","first-page":"e406","DOI":"10.1097\/INF.0b013e31829b80ee","article-title":"Evaluation of risk for late language emergence after in utero antiretroviral drug exposure in HIV-exposed uninfected infants","volume":"32","author":"Rice","year":"2013","journal-title":"Pediatr. Infect. Dis. J."},{"issue":"6","key":"10.1016\/j.reprotox.2018.05.008_bib0060","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1097\/INF.0b013e318284129a","article-title":"Safety of perinatal exposure to antiretroviral medications: developmental outcomes in infants","volume":"32","author":"Sirois","year":"2013","journal-title":"Pediatr. Infect. Dis. J."},{"issue":"9","key":"10.1016\/j.reprotox.2018.05.008_bib0065","doi-asserted-by":"crossref","first-page":"736","DOI":"10.3109\/1061186X.2012.716847","article-title":"Pharmacotherapy in pregnancy; effect of ABC and SLC transporters on drug transport across the placenta and fetal drug exposure","volume":"20","author":"Staud","year":"2012","journal-title":"J. Drug. Target."},{"issue":"2","key":"10.1016\/j.reprotox.2018.05.008_bib0070","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.ajog.2004.01.034","article-title":"Maternal-fetal transfer and amniotic fluid accumulation of protease inhibitors in pregnant women who are infected with human immunodeficiency virus","volume":"191","author":"Chappuy","year":"2004","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"6","key":"10.1016\/j.reprotox.2018.05.008_bib0075","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1097\/00002030-200204120-00008","article-title":"Transplacental passage of protease inhibitors at delivery","volume":"16","author":"Marzolini","year":"2002","journal-title":"AIDS"},{"issue":"3 Pt. 1","key":"10.1016\/j.reprotox.2018.05.008_bib0080","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/S0002-9378(98)70078-X","article-title":"Placental transfer of ritonavir with zidovudine in the ex vivo placental perfusion model","volume":"179","author":"Casey","year":"1998","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"1","key":"10.1016\/j.reprotox.2018.05.008_bib0085","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ejogrb.2011.02.005","article-title":"Atazanavir in pregnancy: impact on neonatal hyperbilirubinemia","volume":"157","author":"Mandelbrot","year":"2011","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"issue":"18","key":"10.1016\/j.reprotox.2018.05.008_bib0090","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1097\/QAD.0b013e32825a69d1","article-title":"Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer","volume":"21","author":"Ripamonti","year":"2007","journal-title":"AIDS"},{"issue":"6","key":"10.1016\/j.reprotox.2018.05.008_bib0095","doi-asserted-by":"crossref","first-page":"620","DOI":"10.2174\/157016209789973628","article-title":"Newborn Clinical Outcome group, Transplacental transfer of antiretroviral drugs and newborn birth weight in HIV-infected pregnant women","volume":"7","author":"Ivanovic","year":"2009","journal-title":"Curr. HIV Res."},{"issue":"6\u20137","key":"10.1016\/j.reprotox.2018.05.008_bib0100","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.placenta.2005.05.007","article-title":"Expression of the multidrug resistance P-glycoprotein (ABCB1 glycoprotein) in the human placenta decreases with advancing gestation","volume":"27","author":"Sun","year":"2006","journal-title":"Placenta"},{"issue":"12","key":"10.1016\/j.reprotox.2018.05.008_bib0105","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1139\/y06-078","article-title":"Expression of breast cancer resistance protein (BCRP\/ABCG2) in human placenta throughout gestation and at term before and after labor","volume":"84","author":"Yeboah","year":"2006","journal-title":"Can. J. Physiol. Pharmacol."},{"issue":"6","key":"10.1016\/j.reprotox.2018.05.008_bib0110","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.reprotox.2004.04.014","article-title":"P-glycoprotein expression and distribution in the rat placenta during pregnancy","volume":"18","author":"Novotna","year":"2004","journal-title":"Reprod. Toxicol."},{"issue":"10","key":"10.1016\/j.reprotox.2018.05.008_bib0115","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1271\/bbb.69.1871","article-title":"Expression level of ABCG2 in the placenta decreases from the mid stage to the end of gestation","volume":"69","author":"Yasuda","year":"2005","journal-title":"Biosci. Biotechnol. Biochem."},{"issue":"2","key":"10.1016\/j.reprotox.2018.05.008_bib0120","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1124\/dmd.31.2.153","article-title":"The presence of xenobiotic transporters in rat placenta","volume":"31","author":"Leazer","year":"2003","journal-title":"Drug. Metab. Dispos."},{"issue":"4","key":"10.1016\/j.reprotox.2018.05.008_bib0125","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1517\/17425255.2015.1005073","article-title":"Regulation of drug transporter expression and function in the placenta","volume":"11","author":"Staud","year":"2015","journal-title":"Expert Opin. Drug. Metab. Toxicol."},{"issue":"4","key":"10.1016\/j.reprotox.2018.05.008_bib0130","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1097\/00002030-200103090-00007","article-title":"Assessment of active transport of HIV protease inhibitors in various cell lines and the in vitro blood\u2013brain barrier","volume":"15","author":"van der Sandt","year":"2001","journal-title":"AIDS"},{"issue":"17","key":"10.1016\/j.reprotox.2018.05.008_bib0135","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1097\/00002030-200211220-00009","article-title":"Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs","volume":"16","author":"Huisman","year":"2002","journal-title":"AIDS"},{"issue":"9","key":"10.1016\/j.reprotox.2018.05.008_bib0140","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1089\/aid.2007.0022","article-title":"Comparison of ABC transporter modulation by atazanavir in lymphocytes and human brain endothelial cells: ABC transporters are involved in the atazanavir-limited passage across an in vitro human model of the blood-brain barrier","volume":"24","author":"Bousquet","year":"2008","journal-title":"AIDS Res. Hum. Retroviruses"},{"issue":"3","key":"10.1016\/j.reprotox.2018.05.008_bib0145","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1128\/AAC.02031-13","article-title":"Role of P-glycoprotein in the distribution of the HIV protease inhibitor atazanavir in the brain and male genital tract","volume":"58","author":"Robillard","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"issue":"4","key":"10.1016\/j.reprotox.2018.05.008_bib0150","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1007\/s11095-012-0942-y","article-title":"Role of drug efflux and uptake transporters in atazanavir intestinal permeability and drug-drug interactions","volume":"30","author":"Kis","year":"2013","journal-title":"Pharm. Res."},{"issue":"3","key":"10.1016\/j.reprotox.2018.05.008_bib0155","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1023\/A:1011924314899","article-title":"Active apical secretory efflux of the HIV protease inhibitors saquinavir and ritonavir in Caco-2 cell monolayers","volume":"15","author":"Alsenz","year":"1998","journal-title":"Pharm. Res."},{"issue":"8","key":"10.1016\/j.reprotox.2018.05.008_bib0160","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1023\/A:1018941328702","article-title":"Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor","volume":"16","author":"Polli","year":"1999","journal-title":"Pharm. Res."},{"issue":"11","key":"10.1016\/j.reprotox.2018.05.008_bib0165","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1097\/00002030-200107270-00004","article-title":"P-glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: potential for accelerated viral drug resistance?","volume":"15","author":"Jones","year":"2001","journal-title":"AIDS"},{"issue":"6","key":"10.1016\/j.reprotox.2018.05.008_bib0170","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/00002030-200104130-00002","article-title":"Differences in the intracellular accumulation of HIV protease inhibitors in vitro and the effect of active transport","volume":"15","author":"Jones","year":"2001","journal-title":"AIDS"},{"issue":"8","key":"10.1016\/j.reprotox.2018.05.008_bib0175","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1093\/jac\/dkq209","article-title":"Protease inhibitors atazanavir, lopinavir and ritonavir are potent blockers, but poor substrates, of ABC transporters in a broad panel of ABC transporter-overexpressing cell lines","volume":"65","author":"Bierman","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"issue":"1","key":"10.1016\/j.reprotox.2018.05.008_bib0180","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1124\/jpet.104.065342","article-title":"HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP\/ABCG2)","volume":"310","author":"Gupta","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"2","key":"10.1016\/j.reprotox.2018.05.008_bib0185","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1177\/135965350701200211","article-title":"Molecular assessment of the potential for renal drug interactions between tenofovir and HIV protease inhibitors","volume":"12","author":"Cihlar","year":"2007","journal-title":"Antivir. Ther."},{"issue":"1","key":"10.1016\/j.reprotox.2018.05.008_bib0190","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/QAD.0000000000000112","article-title":"Interactions of tenofovir and tenofovir disoproxil fumarate with drug efflux transporters ABCB1, ABCG2, and ABCC2; Role in transport across the placenta","volume":"28","author":"Neumanova","year":"2014","journal-title":"AIDS"},{"issue":"5","key":"10.1016\/j.reprotox.2018.05.008_bib0195","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/QAI.0b013e31820fd093","article-title":"Atazanavir pharmacokinetics with and without tenofovir during pregnancy","volume":"56","author":"Mirochnick","year":"2011","journal-title":"J. Acquir. Immune Defic. Syndr."},{"issue":"6","key":"10.1016\/j.reprotox.2018.05.008_bib0200","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1128\/AAC.48.6.2091-2096.2004","article-title":"Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients","volume":"48","author":"Taburet","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.reprotox.2018.05.008_bib0205","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0143-4004(97)90069-2","article-title":"Intrahepatic cholestasis of pregnancy impairs the activities of human placental xenobiotic and steroid metabolizing enzymes in vitro","volume":"18","author":"Pasanen","year":"1997","journal-title":"Placenta"},{"issue":"8","key":"10.1016\/j.reprotox.2018.05.008_bib0210","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2165\/00003088-200443080-00001","article-title":"Drug transfer and metabolism by the human placenta","volume":"43","author":"Syme","year":"2004","journal-title":"Clin. Pharmacokinet."},{"issue":"3","key":"10.1016\/j.reprotox.2018.05.008_bib0215","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/j.1528-1167.2006.00453.x","article-title":"Lack of interactions between breast cancer resistance protein (bcrp\/abcg2) and selected antiepileptic agents","volume":"47","author":"Cerveny","year":"2006","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.reprotox.2018.05.008_bib0220","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/bdd.1993","article-title":"Role of ABCB1, ABCG2, ABCC2 and ABCC5 transporters in placental passage of zidovudine","volume":"37","author":"Neumanova","year":"2016","journal-title":"Biopharm. Drug. Dispos."},{"key":"10.1016\/j.reprotox.2018.05.008_bib0225","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.reprotox.2015.07.070","article-title":"Effect of drug efflux transporters on placental transport of antiretroviral agent abacavir","volume":"57","author":"Neumanova","year":"2015","journal-title":"Reprod. Toxicol."},{"issue":"8","key":"10.1016\/j.reprotox.2018.05.008_bib0230","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.neuropharm.2008.08.032","article-title":"Several major antiepileptic drugs are substrates for human P-glycoprotein","volume":"55","author":"Luna-Tortos","year":"2008","journal-title":"Neuropharmacology"},{"issue":"9","key":"10.1016\/j.reprotox.2018.05.008_bib0235","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1038\/nprot.2007.303","article-title":"Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers","volume":"2","author":"Hubatsch","year":"2007","journal-title":"Nat. Protoc."},{"issue":"11","key":"10.1016\/j.reprotox.2018.05.008_bib0240","doi-asserted-by":"crossref","first-page":"4413","DOI":"10.1002\/jps.21744","article-title":"Comparison of bidirectional lamivudine and zidovudine transport using MDCK, MDCK-MDR1, and Caco-2 cell monolayers","volume":"98","author":"de Souza","year":"2009","journal-title":"J. Pharm. Sci."},{"issue":"2","key":"10.1016\/j.reprotox.2018.05.008_bib0245","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.ejpb.2012.07.020","article-title":"Comparison of brain capillary endothelial cell-based and epithelial (MDCK-MDR1, Caco-2, and VB-Caco-2) cell-based surrogate blood-brain barrier penetration models","volume":"82","author":"Hellinger","year":"2012","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"7","key":"10.1016\/j.reprotox.2018.05.008_bib0250","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1124\/dmd.106.014274","article-title":"Abcg2\/Bcrp1 mediates the polarized transport of antiretroviral nucleosides abacavir and zidovudine","volume":"35","author":"Pan","year":"2007","journal-title":"Drug. Metab. Dispos."},{"issue":"2","key":"10.1016\/j.reprotox.2018.05.008_bib0255","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1093\/toxsci\/kfs160","article-title":"Synchronized activity of organic cation transporter 3 (Oct3\/Slc22a3) and multidrug and toxin extrusion 1 (Mate1\/Slc47a1) transporter in transplacental passage of MPP++ in rat","volume":"128","author":"Ahmadimoghaddam","year":"2012","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.reprotox.2018.05.008_bib0260","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.reprotox.2013.03.001","article-title":"Transfer of metformin across the rat placenta is mediated by organic cation transporter 3 (OCT3\/SLC22A3) and multidrug and toxin extrusion 1 (MATE1\/SLC47A1) protein","volume":"39","author":"Ahmadimoghaddam","year":"2013","journal-title":"Reprod. Toxicol."},{"issue":"3","key":"10.1016\/j.reprotox.2018.05.008_bib0265","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.toxlet.2008.03.007","article-title":"Role of breast cancer resistance protein (Bcrp\/Abcg2) in fetal protection during gestation in rat","volume":"178","author":"Cygalova","year":"2008","journal-title":"Toxicol. Lett."},{"issue":"3","key":"10.1016\/j.reprotox.2018.05.008_bib0270","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1124\/jpet.109.160564","article-title":"Transplacental pharmacokinetics of glyburide, rhodamine 123, and BODIPY FL prazosin: effect of drug efflux transporters and lipid solubility","volume":"331","author":"Cygalova","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"9","key":"10.1016\/j.reprotox.2018.05.008_bib0275","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1124\/dmd.109.028258","article-title":"Identification and profiling of circulating metabolites of atazanavir, a HIV protease inhibitor","volume":"37","author":"ter Heine","year":"2009","journal-title":"Drug. Metab. Dispos."},{"issue":"3","key":"10.1016\/j.reprotox.2018.05.008_bib0280","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1093\/jac\/dkq468","article-title":"Pharmacokinetics of plasma lopinavir\/ritonavir following the administration of 400\/100 mg, 200\/150 mg and 200\/50 mg twice daily in HIV-negative volunteers","volume":"66","author":"Jackson","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"issue":"3","key":"10.1016\/j.reprotox.2018.05.008_bib0285","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrd3028","article-title":"Membrane transporters in drug development","volume":"9","author":"C. International Transporter","year":"2010","journal-title":"Nat. Rev. Drug. Discov."},{"issue":"1","key":"10.1016\/j.reprotox.2018.05.008_bib0290","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/clpt.2013.81","article-title":"In vitro methods to support transporter evaluation in drug discovery and development","volume":"94","author":"Brouwer","year":"2013","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.reprotox.2018.05.008_bib0295","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejpb.2016.12.027","article-title":"Quantitative analysis of lab-to-lab variability in Caco-2 permeability assays","volume":"114","author":"Lee","year":"2017","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"2","key":"10.1016\/j.reprotox.2018.05.008_bib0300","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1002\/jps.21010","article-title":"Variability in Caco-2 and MDCK cell-based intestinal permeability assays","volume":"97","author":"Volpe","year":"2008","journal-title":"J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.reprotox.2018.05.008_bib0305","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1124\/jpet.106.105023","article-title":"Expression and transport activity of breast cancer resistance protein (Bcrp\/Abcg2) in dually perfused rat placenta and HRP-1 cell line","volume":"319","author":"Staud","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"3","key":"10.1016\/j.reprotox.2018.05.008_bib0310","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.reprotox.2006.01.007","article-title":"P-glycoprotein in the placenta: expression, localization, regulation and function","volume":"22","author":"Ceckova-Novotna","year":"2006","journal-title":"Reprod. Toxicol."},{"issue":"1","key":"10.1016\/j.reprotox.2018.05.008_bib0315","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3109\/03602532.2010.512293","article-title":"Fetoprotective activity of breast cancer resistance protein (BCRP, ABCG2): expression and function throughout pregnancy","volume":"43","author":"Hahnova-Cygalova","year":"2011","journal-title":"Drug. Metab. Rev."},{"issue":"3","key":"10.1016\/j.reprotox.2018.05.008_bib0320","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1517\/17425255.2013.741589","article-title":"Species differences in drug transporters and implications for translating preclinical findings to humans","volume":"9","author":"Chu","year":"2013","journal-title":"Expert Opin. Drug. Metab. Toxicol."},{"issue":"1\u20132","key":"10.1016\/j.reprotox.2018.05.008_bib0325","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ejps.2008.06.008","article-title":"Identification of interspecies difference in efflux transporters of hepatocytes from dog, rat, monkey and human","volume":"35","author":"Li","year":"2008","journal-title":"Eur. J. Pharm. Sci."},{"issue":"9","key":"10.1016\/j.reprotox.2018.05.008_bib0330","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1124\/dmd.108.021337","article-title":"Prominent expression of xenobiotic efflux transporters in mouse extraembryonic fetal membranes compared with placenta","volume":"36","author":"Aleksunes","year":"2008","journal-title":"Drug. Metab. Dispos."},{"issue":"10","key":"10.1016\/j.reprotox.2018.05.008_bib0335","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.placenta.2007.03.010","article-title":"Breast cancer resistance protein (Bcrp1\/Abcg2) in mouse placenta and yolk sac: ontogeny and its regulation by progesterone","volume":"28","author":"Kalabis","year":"2007","journal-title":"Placenta"}],"container-title":["Reproductive Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890623818300455?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890623818300455?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:47:09Z","timestamp":1760190429000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0890623818300455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":67,"alternative-id":["S0890623818300455"],"URL":"https:\/\/doi.org\/10.1016\/j.reprotox.2018.05.008","relation":{},"ISSN":["0890-6238"],"issn-type":[{"value":"0890-6238","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interactions of protease inhibitors atazanavir and ritonavir with ABCB1, ABCG2, and ABCC2 transporters: Effect on transplacental disposition in rats","name":"articletitle","label":"Article Title"},{"value":"Reproductive Toxicology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.reprotox.2018.05.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}